{"id":350444,"date":"2026-11-17T14:52:34","date_gmt":"2026-11-17T09:22:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350444"},"modified":"2026-11-17T14:52:34","modified_gmt":"2026-11-17T09:22:34","slug":"senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/","title":{"rendered":"3 Senior Living Homes Builder, Global IT Services Leader and Branded Medicines Company Stocks With a Strong Future Roadmap: Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals: ROE of 13.6% to 43.4% and FY22 to FY26 revenue CAGR of 8.5% to 50.2%. Prices as of 16 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>senior housing, IT and medicine stocks<\/strong> to watch are <strong>Ashiana Housing<\/strong>, <strong>Tata Consultancy Services<\/strong> and <strong>Emcure Pharmaceuticals<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>13.6% to 43.4%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 8.5% to 50.2%. Tata Consultancy Services has the highest return on equity at 43.4%, while Ashiana Housing has the fastest revenue growth at 50.2% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Senior housing, IT and medicine stocks bring together companies with a visible plan for the years ahead. Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals cover a residential developer, an IT services company and a pharmaceuticals company.<\/p>\n<p>This list covers three senior housing, IT and medicine stocks with complete current figures: Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#What_Are_Senior_Housing_IT_and_Medicine_Stocks\" title=\"What Are Senior Housing, IT and Medicine Stocks?\">What Are Senior Housing, IT and Medicine Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Senior_Housing_IT_and_Medicine_Stocks_at_a_Glance\" title=\"Senior Housing, IT and Medicine Stocks at a Glance\">Senior Housing, IT and Medicine Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Why_Do_Senior_Housing_IT_and_Medicine_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Senior Housing, IT and Medicine Stocks Have a Strong Roadmap in India?\">Why Do Senior Housing, IT and Medicine Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Why_Ashiana_Housing_Features_Among_These_Senior_Housing_IT_and_Medicine_Stocks\" title=\"Why Ashiana Housing Features Among These Senior Housing, IT and Medicine Stocks\">Why Ashiana Housing Features Among These Senior Housing, IT and Medicine Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Why_Tata_Consultancy_Services_Features_Among_These_Senior_Housing_IT_and_Medicine_Stocks\" title=\"Why Tata Consultancy Services Features Among These Senior Housing, IT and Medicine Stocks\">Why Tata Consultancy Services Features Among These Senior Housing, IT and Medicine Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Why_Emcure_Pharmaceuticals_Features_Among_These_Senior_Housing_IT_and_Medicine_Stocks\" title=\"Why Emcure Pharmaceuticals Features Among These Senior Housing, IT and Medicine Stocks\">Why Emcure Pharmaceuticals Features Among These Senior Housing, IT and Medicine Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Ashiana_Housing_vs_Tata_Consultancy_Services_vs_Emcure_Pharmaceuticals_on_Key_Financials\" title=\"Ashiana Housing vs Tata Consultancy Services vs Emcure Pharmaceuticals on Key Financials\">Ashiana Housing vs Tata Consultancy Services vs Emcure Pharmaceuticals on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Key_Risks_to_Check_Before_Investing_in_Senior_Housing_IT_and_Medicine_Stocks\" title=\"Key Risks to Check Before Investing in Senior Housing, IT and Medicine Stocks\">Key Risks to Check Before Investing in Senior Housing, IT and Medicine Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Final_Thoughts_on_Senior_Housing_IT_and_Medicine_Stocks\" title=\"Final Thoughts on Senior Housing, IT and Medicine Stocks\">Final Thoughts on Senior Housing, IT and Medicine Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#What_are_senior_housing_IT_and_medicine_stocks\" title=\"What are senior housing, IT and medicine stocks?\">What are senior housing, IT and medicine stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Which_senior_housing_IT_and_medicine_stocks_are_covered_in_this_list\" title=\"Which senior housing, IT and medicine stocks are covered in this list?\">Which senior housing, IT and medicine stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Why_do_senior_housing_IT_and_medicine_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do senior housing, IT and medicine stocks have a strong future roadmap in India?\">Why do senior housing, IT and medicine stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#How_has_Ashiana_Housing_performed_financially\" title=\"How has Ashiana Housing performed financially?\">How has Ashiana Housing performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#How_has_Tata_Consultancy_Services_performed_financially\" title=\"How has Tata Consultancy Services performed financially?\">How has Tata Consultancy Services performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#How_has_Emcure_Pharmaceuticals_performed_financially\" title=\"How has Emcure Pharmaceuticals performed financially?\">How has Emcure Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#What_risks_should_investors_check_before_buying_senior_housing_IT_and_medicine_stocks\" title=\"What risks should investors check before buying senior housing, IT and medicine stocks?\">What risks should investors check before buying senior housing, IT and medicine stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/senior-living-homes-builder-global-it-services-leader-and-branded-medicines-company-stocks-roadmap-grassland-list\/#Is_this_list_of_senior_housing_IT_and_medicine_stocks_investment_advice\" title=\"Is this list of senior housing, IT and medicine stocks investment advice?\">Is this list of senior housing, IT and medicine stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Senior_Housing_IT_and_Medicine_Stocks\"><\/span><strong>What Are Senior Housing, IT and Medicine Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Senior housing, IT and medicine stocks<\/strong> are listed companies that build and sell apartments and senior living homes, provide IT services and consulting to large global clients, and make and sell medicines in India and global markets. Their earnings depend on home sales, client technology programmes and medicine demand.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Senior_Housing_IT_and_Medicine_Stocks_at_a_Glance\"><\/span><strong>Senior Housing, IT and Medicine Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ashiana\/ashiana-housing-ltd-share-price-today\">Ashiana Housing<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">352.45<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,586<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">30.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">30.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.35<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/tcs\/tata-consultancy-services-ltd-share-price-today\">Tata Consultancy Services<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,405<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">904,522<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">43.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.10<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/emcure\/emcure-pharmaceuticals-ltd-share-price-today\">Emcure Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,338.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33,487<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.31<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a <strong>P\/E<\/strong> below their industry P\/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing senior housing, IT and medicine stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Senior_Housing_IT_and_Medicine_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Senior Housing, IT and Medicine Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Senior housing, IT and medicine stocks have a strong roadmap in India because steady demand for new homes, large client technology programmes and wider access to medicines keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Residential projects.<\/strong> Families look for well planned homes.<\/li>\n<li><strong>IT services.<\/strong> Large clients run long digital programmes.<\/li>\n<li><strong>Medicines.<\/strong> Hospitals and patients need reliable supply.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Ashiana_Housing_Features_Among_These_Senior_Housing_IT_and_Medicine_Stocks\"><\/span><strong>Why Ashiana Housing Features Among These Senior Housing, IT and Medicine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the <strong>senior housing, IT and medicine stocks<\/strong> on this list, Ashiana Housing develops mid-income residential projects and senior living communities in cities such as the Delhi region, Jaipur and Chennai. It is known for its focus on construction quality and timely delivery.<\/p>\n<p>The company has a return on equity of 13.6%, a debt to equity ratio of 0.35 and a <strong>market capitalisation<\/strong> of Rs 3,586 crore. The stock trades at a <strong>P\/E<\/strong> of 30.3, below the industry P\/E of 30.7.<\/p>\n<p>Revenue rose from Rs 234 crore in FY22 to Rs 1,187 crore in FY26, a compound annual growth rate of 50.2%. Net profit grew from Rs 27.9 crore in FY23 to Rs 118 crore in FY26, which works out to a compound annual growth rate of 61.7%.<\/p>\n<p><strong>Roadmap:<\/strong> The company is launching new phases in established markets and growing its senior living portfolio. A reputation for delivery supports sales in its projects.<\/p>\n<p><strong>What to watch:<\/strong> Track sales bookings, project launches and deliveries.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Tata_Consultancy_Services_Features_Among_These_Senior_Housing_IT_and_Medicine_Stocks\"><\/span><strong>Why Tata Consultancy Services Features Among These Senior Housing, IT and Medicine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the home builder, software giant and drug maker shares on this list, Tata Consultancy Services is India&#8217;s largest information technology services company, offering consulting, application development, cloud, data and business process services to global clients from the Tata group.<\/p>\n<p>Revenue rose from Rs 195,772 crore in FY22 to Rs 271,423 crore in FY26, a compound annual growth rate of 8.5%. Net profit grew from Rs 38,449 crore in FY22 to Rs 49,454 crore in FY26, which works out to a compound annual growth rate of 6.5%.<\/p>\n<p>The company has a return on equity of 43.4%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 904,522 crore. The stock trades at a P\/E of 17.4, below the industry P\/E of 17.6.<\/p>\n<p><strong>Roadmap:<\/strong> The company is investing in artificial intelligence, cloud and data capabilities and in large multi-year transformation programmes with global clients. A broad client base across industries gives its revenue stability.<\/p>\n<p><strong>What to watch:<\/strong> Track order book trends, demand for artificial intelligence services and currency movements.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Emcure_Pharmaceuticals_Features_Among_These_Senior_Housing_IT_and_Medicine_Stocks\"><\/span><strong>Why Emcure Pharmaceuticals Features Among These Senior Housing, IT and Medicine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.<\/p>\n<p>In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%.<\/p>\n<p>Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> It is strengthening its domestic branded portfolio in women&#8217;s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.<\/p>\n<p><strong>What to watch:<\/strong> Look at the growth of the India branded business and the pace of new launches abroad.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Ashiana_Housing_vs_Tata_Consultancy_Services_vs_Emcure_Pharmaceuticals_on_Key_Financials\"><\/span><strong>Ashiana Housing vs Tata Consultancy Services vs Emcure Pharmaceuticals on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three senior housing, IT and medicine stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ashiana Housing<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">234<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,187<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">50.2%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">118<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.9%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Tata Consultancy Services<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">195,772<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">271,423<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">8.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">49,454<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.2%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Emcure Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,919<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,335<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">941<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Tata Consultancy Services posts the highest return on equity in this group at 43.4%. Tata Consultancy Services has the largest FY26 revenue at Rs 271,423 crore, and Ashiana Housing shows the fastest revenue growth with a 50.2% compound annual rate. A useful habit with senior housing, IT and medicine stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Senior_Housing_IT_and_Medicine_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Senior Housing, IT and Medicine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these <strong>senior housing, IT and medicine stocks<\/strong>, the main points are:<\/p>\n<ul>\n<li><strong>Housing cycles.<\/strong> Real estate and building demand can vary with rates and sentiment.<\/li>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter senior housing, IT and medicine stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Senior_Housing_IT_and_Medicine_Stocks\"><\/span><strong>Final Thoughts on Senior Housing, IT and Medicine Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Senior housing, IT and medicine stocks suit investors who prefer to study business strength before price moves. Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals each have a clear plan to grow. Based on the 16 November 2026 close, Ashiana Housing trades at Rs 352.45, Tata Consultancy Services at Rs 2,405 and Emcure Pharmaceuticals at Rs 2,338.8.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track senior housing, IT and medicine stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_senior_housing_IT_and_medicine_stocks\"><\/span><strong>What are senior housing, IT and medicine stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>Senior housing, IT and medicine stocks<\/strong> are listed companies that build and sell apartments and senior living homes, provide IT services and consulting to large global clients, and make and sell medicines in India and global markets. Their earnings depend on home sales, client technology programmes and medicine demand. This list looks at three of them, Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_senior_housing_IT_and_medicine_stocks_are_covered_in_this_list\"><\/span><strong>Which senior housing, IT and medicine stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals. Based on the 16 November 2026 close, Ashiana Housing traded at Rs 352.45, Tata Consultancy Services at Rs 2,405 and Emcure Pharmaceuticals at Rs 2,338.8. Their return on equity ranges from <strong>13.6% to 43.4%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 8.5% to 50.2%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_senior_housing_IT_and_medicine_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do senior housing, IT and medicine stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Senior housing, IT and medicine stocks have a strong roadmap in India because steady demand for new homes, large client technology programmes and wider access to medicines keep widening the market for these companies. The main drivers are as follows. Residential projects. Families look for well planned homes. IT services. Large clients run long digital programmes. Medicines. Hospitals and patients need reliable supply. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Ashiana_Housing_performed_financially\"><\/span><strong>How has Ashiana Housing performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 234 crore in FY22 to Rs 1,187 crore in FY26, a compound annual growth rate of 50.2%. Net profit grew from Rs 27.9 crore in FY23 to Rs 118 crore in FY26, which works out to a compound annual growth rate of 61.7%. The company has a return on equity of 13.6%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 3,586 crore. The stock trades at a P\/E of 30.3, below the industry P\/E of 30.7. Looking ahead, the company is launching new phases in established markets and growing its senior living portfolio. A reputation for delivery supports sales in its projects.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Tata_Consultancy_Services_performed_financially\"><\/span><strong>How has Tata Consultancy Services performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 195,772 crore in FY22 to Rs 271,423 crore in FY26, a compound annual growth rate of 8.5%. Net profit grew from Rs 38,449 crore in FY22 to Rs 49,454 crore in FY26, which works out to a compound annual growth rate of 6.5%. The company has a return on equity of 43.4%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 904,522 crore. The stock trades at a P\/E of 17.4, below the industry P\/E of 17.6. Looking ahead, the company is investing in artificial intelligence, cloud and data capabilities and in large multi-year transformation programmes with global clients. A broad client base across industries gives its revenue stability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Emcure_Pharmaceuticals_performed_financially\"><\/span><strong>How has Emcure Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women&#8217;s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_senior_housing_IT_and_medicine_stocks\"><\/span><strong>What risks should investors check before buying senior housing, IT and medicine stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying senior housing, IT and medicine stocks. Housing cycles. Real estate and building demand can vary with rates and sentiment. Client spending. Technology budgets can vary with global conditions. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_senior_housing_IT_and_medicine_stocks_investment_advice\"><\/span><strong>Is this list of senior housing, IT and medicine stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are senior housing, IT and medicine stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Senior housing, IT and medicine stocks are listed companies that build and sell apartments and senior living homes, provide IT services and consulting to large global clients, and make and sell medicines in India and global markets. Their earnings depend on home sales, client technology programmes and medicine demand. This list looks at three of them, Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which senior housing, IT and medicine stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals. Based on the 16 November 2026 close, Ashiana Housing traded at Rs 352.45, Tata Consultancy Services at Rs 2,405 and Emcure Pharmaceuticals at Rs 2,338.8. Their return on equity ranges from 13.6% to 43.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 50.2%.\"}},{\"@type\":\"Question\",\"name\":\"Why do senior housing, IT and medicine stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Senior housing, IT and medicine stocks have a strong roadmap in India because steady demand for new homes, large client technology programmes and wider access to medicines keep widening the market for these companies. The main drivers are as follows. Residential projects. Families look for well planned homes. IT services. Large clients run long digital programmes. Medicines. Hospitals and patients need reliable supply. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Ashiana Housing performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 234 crore in FY22 to Rs 1,187 crore in FY26, a compound annual growth rate of 50.2%. Net profit grew from Rs 27.9 crore in FY23 to Rs 118 crore in FY26, which works out to a compound annual growth rate of 61.7%. The company has a return on equity of 13.6%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 3,586 crore. The stock trades at a P\/E of 30.3, below the industry P\/E of 30.7. Looking ahead, the company is launching new phases in established markets and growing its senior living portfolio. A reputation for delivery supports sales in its projects.\"}},{\"@type\":\"Question\",\"name\":\"How has Tata Consultancy Services performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 195,772 crore in FY22 to Rs 271,423 crore in FY26, a compound annual growth rate of 8.5%. Net profit grew from Rs 38,449 crore in FY22 to Rs 49,454 crore in FY26, which works out to a compound annual growth rate of 6.5%. The company has a return on equity of 43.4%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 904,522 crore. The stock trades at a P\/E of 17.4, below the industry P\/E of 17.6. Looking ahead, the company is investing in artificial intelligence, cloud and data capabilities and in large multi-year transformation programmes with global clients. A broad client base across industries gives its revenue stability.\"}},{\"@type\":\"Question\",\"name\":\"How has Emcure Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying senior housing, IT and medicine stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying senior housing, IT and medicine stocks. Housing cycles. Real estate and building demand can vary with rates and sentiment. Client spending. Technology budgets can vary with global conditions. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of senior housing, IT and medicine stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Senior Housing, IT and Medicine Stocks with a strong future roadmap: Ashiana Housing, Tata Consultancy Services and Emcure Pharmaceuticals. Compare price, valuation, return on equity and revenue growth as of 16 November 2026.<\/p>\n","protected":false},"author":35,"featured_media":350443,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[9375,3803,13907,25040,25039,25043,25042,25038,25041,2581],"class_list":["post-350444","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-ashiana-housing","tag-best-stocks","tag-emcure-pharmaceuticals","tag-home-builder","tag-it-and-medicine-stocks","tag-it-outsourcing-and-branded-drugs-stocks","tag-residential-projects","tag-senior-housing","tag-software-giant-and-drug-maker-shares","tag-tata-consultancy-services"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350443"],"rank_math_title":["Housing, IT Services and Pharma Stocks"],"rank_math_description":["Compare 3 senior housing, IT and medicine stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 16 Nov 2026."],"rank_math_focus_keyword":["senior housing, IT and medicine stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-senior-living-homes-builder-global-it-services-leader-and-branded-medicines.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350444"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350444\/revisions"}],"predecessor-version":[{"id":350445,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350444\/revisions\/350445"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350443"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}